Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Melanoma 23Skin Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 8Carcinoma, Basal Cell 8Carcinoma, Merkel Cell 7Neoplasms 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Cutaneous Squamous Cell Carcinoma 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Uveal Melanoma 2Sarcoma 2Pancreatic Neoplasms 2Kidney Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck 1Recurrence 1Prostatic Neoplasms 1

Interventions

cemiplimab 1Therapeutics 1Radiation, Ionizing 1Mass Spectrometry 1Imatinib Mesylate 1Docetaxel 1Chromatography, High Pressure Liquid 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × cemiplimab × Dermatologic × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡